Investors

Ikena has raised capital from leading biopharma investors in the healthcare industry. We completed a $49 million Series A financing by OrbiMed and Atlas Venture in December 2017. In January 2019, as part of the Bristol Myers Squibb global strategic collaboration, Ikena received an undisclosed equity investment.

Merck
Merck
Celgene Corporation

Reach out to find out more about how we are discovering and developing cancer therapies.